drug: aripiprazole |
|
|
| Clinical class | atypical antipsychotic |
| Action | partial dopamine D2 receptor agonist/antagonist |
| Chemical class | quinolinone derivative |
| CSA schedule | none |
| DEA number | none |
| Associated with (substance-related)
|
disorders: none |
| Availability | prescription |
U.S. Preparations:
- Abilify® (Bristol-Myers Squibb) FDA approved for treatment of:
11.15.2002 Schizophrenia
8.28.2003 Schizophrenia including maintenance up to 26 weeks
9.29.2004 Acute manic or mixed episodes associated with Bipolar Disorder
3.1.2005 Maintenance therapy in Bipolar I Disorder
9.20.2006 (intramuscular) agitation associated with Schizophrenia or Bipolar Disorder, manic or mixed
10.29.2007 treatment of Schizophrenia in adolescents aged 13-17
11.16.2007 adjunctive treatment of Major Depressive Disorder
US prescribing information
- Abilify®
Discmelt™ (Otsuka) FDA approved for treatment of
:
6.7.2006 Schizophrenia; acute manic or mixed episodes associated with Bipolar Disorder
10.29.2007 treatment of Schizophrenia in adolescents aged 13-17
11.16.2007 adjunctive treatment of Major Depressive Disorder
US prescribing information
Other Preparations:
- Abilitat